Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)

Published:2020-01-07 Issue:4 Volume:22 Page:713-722
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Damman Kevin¹,Beusekamp Joost C.¹,Boorsma Eva M.¹,Swart Henk P.²,Smilde Tom D.J.³,Elvan Arif⁴,Eck J.W. Martijn⁵,Heerspink Hiddo J.L.¹⁶,Voors Adriaan A.¹

Affiliation:

1. University of Groningen University Medical Center Groningen Groningen The Netherlands

2. Antonius Ziekenhuis Sneek Sneek The Netherlands

3. TREANT zorggroep Emmen The Netherlands

4. Department of Cardiology ISALA Zwolle The Netherlands

5. Jeroen Bosch Ziekenhuis Den Bosch The Netherlands

6. The George Institute for Global Health Sydney Australia

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1713

Reference25 articles.

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

3. Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE–TIMI 58 for the basic science community

4. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

5. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

Cited by 314 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies;Chemico-Biological Interactions;2024-11

2. Timing of sodium–glucose cotransporter 2 inhibitor initiation and post‐discharge outcomes in acute heart failure with diabetes: A population‐based cohort study;European Journal of Heart Failure;2024-09-12

3. Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis;Frontiers in Cardiovascular Medicine;2024-09-11

4. A Trajetória das Gliflozinas: Da Casca da Macieira à Redução de Mortalidade Total na Insuficiência Cardíaca;ABC Heart Failure & Cardiomyopathy;2024-09-06

5. Diuretic Combination Therapy in Acute Heart Failure: An Updated Review;Current Pharmaceutical Design;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3